| Age, years | Sex, F/M (% female) | MMSE score at baseline | CSF Aβ42 (pg/ml) | CSF tau (pg/ml) | CSF p-tau (pg/ml) |
---|
Control subjects, n = 40 | 64.5 ± 8.2 | 19/21 (48%) | 28.3 ± 1.7 | 1086 ± 161 | 228 ± 64 | 40 ± 9 |
MCI, n = 40 | 64.5 ± 8.1 | 19/21 (48%) | 26.3 ± 2.3* | 839 ± 297* | 481 ± 256* | 69 ± 33* |
sMCI, n = 23 | 63.7 ± 7.4 | 11/12 (48%) | 26.7 ± 2.0 | 941 ± 306† | 338 ± 182† | 51 ± 21 |
MCI-ADa, n = 14 | 65.6 ± 9.0 | 7/7 (50%) | 25.9 ± 2.7† | 632 ± 84*,$ | 722 ± 186*,$ | 99 ± 28*,$ |
AD dementia, n = 40 | 64.6 ± 8.1 | 19/21 (48%) | 21.6 ± 3.9* | 640 ± 91*,‡,$ | 740 ± 433*,‡,$ | 94 ± 47*,‡,$ |
- Abbreviations: Aβ
42
Amyloid-β 1–42, AD Alzheimer’s disease, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, MMSE Mini Mental State Examination, p-tau Tau phosphorylated at threonine 181, sMCI Stable mild cognitive impairment
- Data are displayed as mean ± SD unless otherwise indicated. Analysis of variance with post hoc Bonferroni corrections or chi-square tests were used when appropriate. CSF Aβ42, total tau, and p-tau were logarithmically transformed for the analyses because of skewed values; in the table, crude values are shown
- aMCI patients progressing to another form of dementia (n=3) were excluded
- *p < 0.01 vs controls
- †p < 0.05 vs controls
- ‡p < 0.01 vs all MCI patients
- $p < 0.01 vs sMCI patients